| Description |
JNJ-39758979 is a selective, high-affinity histamine H4 receptor antagonist with a Ki of 12.5 nM.
|
| Related Catalog |
|
| Target |
Ki: 12.5 nM (histamine H4 receptor)[1]
|
| In Vitro |
JNJ-39758979 is a selective, high-affinity histamine H4 receptor antagonist with a Ki of 12.5 nM. The affinity of JNJ-39758979 for the rat (Ki=188 nM) and guinea pig H4R (Ki=306 nM) is moderate, and JNJ-39758979 has little if any affinity for the dog H4R (Ki≥10 μM). JNJ-39758979 is metabolically stable (t1/2 >120 min) when incubated in vitro with human, rat, dog, or monkey liver microsomes[1].
|
| In Vivo |
JNJ-39758979 shows dose-proportional pharmacokinetic (PK) in rat in the range of 2 to 500 mpK. JNJ-39758979 rapidly reaches the kidneys and liver (mean tmax=2.0 h). The elimination of JNJ-39758979 is slow from the brain, liver, and kidneys, with mean t1/2 values of 42.5, 22.3, and 20.5 h, respectively. The highest exposure (based on Cmax and AUC0-inf values) is observed in the liver followed by the kidney and brain. Tissue-to-plasma ratios for liver and kidney range from 23.2 to 95.8; the tissue-to-plasma ratios in brain increases with time from 0.256 to 22.7 up to 48 h after dosing. JNJ-39758979 is able to inhibit histamine-induced itch at doses of 5 and 20 mg/kg in mice. JNJ-39758979 exhibits dose-dependent inhibition of the clinical score in a mouse collagen-induced arthritis model[1].
|
| Animal Admin |
The model of histamine-induced scratching in C57/bl6 mice (n=6 to 8 per group) is used to judge the antipruritic effects of JNJ-39758979. JNJ-39758979 is given p.o. in 20% hydroxypropyl-β-cyclodextran 30 min before an intradermal injection of histamine (100 μg). Bouts of scratching are calculated using an automated system. Immediately after histamine injection, mice are placed in containers above a solenoid, and magnets previously placed on the mouse ear generate scratch-specific signals that are counted over a 20 min time span[1].
|
| References |
[1]. Savall BM, et al. Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H₄ receptor antagonists. J Med Chem. 2014 Mar 27;57(6):2429-39.
|
